首页> 外文期刊>Journal of chemical information and modeling >Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification
【24h】

Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification

机译:通过基于形状的虚拟筛选和基于结构的分子修饰相结合,发现和设计三环支架作为蛋白激酶CK2(CK2)抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Protein kinase CK2 (CK2), a ubiquitous serine/threonine protein kinase for hundreds of endogenous substrates, serves as an attractive anticancer target. One of its most potent inhibitors, CX-4945, has entered a phase I clinical trial. Herein we present an integrated workflow combining shape-based virtual screening for the identification of novel CK2 inhibitors. A shape-based model derived from CX-4945 was built, and the subsequent virtual screening led to the identification of several novel scaffolds with high shape similarity to that of CX-4945. Among them two tricyclic scaffolds named [1,2,4]triazolo[4,3-c] quinazolin and [1,2,4]triazolo[4,3-a]quinoxalin attracted us the most. Combining strictly chemical similarity analysis, a second-round shape-based screening was performed based on the two tricyclic scaffolds, leading to 28 derivatives. These compounds not only targeted CK2 with potent and dose-dependent activities but also showed acceptable antiproliferative effects against a series of cancer cell lines. Our workflow supplies a high efficient strategy in the identification of novel CK2 inhibitors. Compounds reported here can serve as ideal leads for further modifications.
机译:蛋白激酶CK2(CK2)是适用于数百种内源性底物的普遍存在的丝氨酸/苏氨酸蛋白激酶,可作为有吸引力的抗癌靶标。其最有效的抑制剂之一CX-4945已进入I期临床试验。在这里,我们提出了一个集成的工作流程,结合了基于形状的虚拟筛选来识别新型CK2抑制剂。建立了从CX-4945衍生的基于形状的模型,随后的虚拟筛选导致鉴定了几种与CX-4945具有高度相似性的新型支架。其中两个名为[1,2,4] triazolo [4,3-c]喹唑啉和[1,2,4] triazolo [4,3-a] quinoxalin的三环支架最吸引我们。结合严格的化学相似性分析,基于两个三环支架进行了第二轮基于形状的筛选,得到28个衍生物。这些化合物不仅以有效和剂量依赖性的活性靶向CK2,而且还显示出对一系列癌细胞的可接受的抗增殖作用。我们的工作流程为鉴定新型CK2抑制剂提供了高效的策略。此处报道的化合物可作为进一步修饰的理想线索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号